Cargando…
Balancing the interplay of histone deacetylases and non-coding genomes: a step closer to understand the landscape of cancer treatment
Histone deacetylase (HDAC) inhibitors have enormous therapeutic potential as effective epigenetic regulators, and now with the focus on the selective HDAC6 inhibitor in ongoing clinical trials, more advantages over other non-selective pan-HDAC inhibitors are foreseeable. As it is of paramount import...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657130/ https://www.ncbi.nlm.nih.gov/pubmed/37978516 http://dx.doi.org/10.1186/s12920-023-01724-3 |